AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 21.665 USD 2.34% Market Closed
Market Cap: 659.3m USD
Have any thoughts about
AnaptysBio Inc?
Write Note

Wall Street
Price Targets

ANAB Price Targets Summary
AnaptysBio Inc

Wall Street analysts forecast ANAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ANAB is 55.451 USD with a low forecast of 30.3 USD and a high forecast of 94.5 USD.

Lowest
Price Target
30.3 USD
40% Upside
Average
Price Target
55.451 USD
156% Upside
Highest
Price Target
94.5 USD
336% Upside

ANAB Last Price Targets
AnaptysBio Inc

The latest public price target was made on Nov 6, 2024 by David Risinger from Leerink Partners , who expects ANAB stock to rise by 108% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
David Risinger
Leerink Partners
45 USD
Upside 108%
2 weeks ago
Nov 6, 2024
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners
StreetInsider
Emily Bodnar
H.C. Wainwright
52 USD
Upside 140%
2 weeks ago
Nov 6, 2024
AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright
StreetInsider
Yatin Suneja
Guggenheim
90 USD
Upside 315%
1 month ago
Oct 21, 2024
AnaptysBio (ANAB) PT Raised to $90 at Guggenheim
StreetInsider
Yasmeen Rahimi
Piper Sandler
80 USD
Upside 269%
1 month ago
Oct 15, 2024
Piper Sandler Reiterates Overweight Rating on AnaptysBio (ANAB)
StreetInsider
David Risinger
New Street
35 USD
Upside 62%
1 month ago
Oct 3, 2024
Leerink Partners Reiterates Outperform Rating on AnaptysBio (ANAB)
StreetInsider
Joon Lee
Truist Financial
30 USD
Upside 38%
3 months ago
Aug 15, 2024
AnaptysBio price target raised to $30 from $20 at Truist
TheFly
David Risinger
Leerink Partners
47 USD
Upside 117%
7 months ago
Apr 16, 2024
AnaptysBio initiated with an Outperform at Leerink
TheFly
Show More Price Targets
Show Less Price Targets
David Risinger
Leerink Partners
Price Target 45 USD
Upside/Downside 108%
View Source
Emily Bodnar
H.C. Wainwright
Price Target 52 USD
Upside/Downside 140%
View Source
Yatin Suneja
Guggenheim
Price Target 90 USD
Upside/Downside 315%
View Source
Yasmeen Rahimi
Piper Sandler
Price Target 80 USD
Upside/Downside 269%
View Source
David Risinger
New Street
Price Target 35 USD
Upside/Downside 62%
View Source
Joon Lee
Truist Financial
Price Target 30 USD
Upside/Downside 38%
View Source
David Risinger
Leerink Partners
Price Target 47 USD
Upside/Downside 117%
View Source
Show More Price Targets
Show Less Price Targets
AnaptysBio Inc Competitors:
Price Targets
SRZN
Surrozen Inc
276% Upside
ALKS
Alkermes Plc
20% Upside
BMRN
Biomarin Pharmaceutical Inc
55% Upside
002675
Yantai Dongcheng Biochemicals Co Ltd
32% Upside
SIGHT
Gensight Biologics SA
22% Upside
BONEX
Bonesupport Holding AB
5% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
21% Upside
PAR
Paradigm Biopharmaceuticals Ltd
48% Upside

Revenue
Forecast

Revenue Estimate
AnaptysBio Inc

For the last 8 years the compound annual growth rate for AnaptysBio Inc's revenue is 0%. The projected CAGR for the next 3 years is 42%.

0%
Past Growth
42%
Estimated Growth
Estimates Accuracy
7%
Average Beat

Operating Income
Forecast

Operating Income Estimate
AnaptysBio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
AnaptysBio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-23%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ANAB's stock price target?
Price Target
55.451 USD

According to Wall Street analysts, the average 1-year price target for ANAB is 55.451 USD with a low forecast of 30.3 USD and a high forecast of 94.5 USD.

What is AnaptysBio Inc's Revenue forecast?
Projected CAGR
42%

For the last 8 years the compound annual growth rate for AnaptysBio Inc's revenue is 0%. The projected CAGR for the next 3 years is 42%.

Back to Top